These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 20415602)
21. Silencing neurodegenerative disease: bringing RNA interference to the clinic. Rodriguez-Lebron E; Gonzalez-Alegre P Expert Rev Neurother; 2006 Feb; 6(2):223-33. PubMed ID: 16466302 [TBL] [Abstract][Full Text] [Related]
22. RNA interference as an anticancer therapy: a patent perspective. Dykxhoorn DM Expert Opin Ther Pat; 2009 Apr; 19(4):475-91. PubMed ID: 19441927 [TBL] [Abstract][Full Text] [Related]
23. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225 [TBL] [Abstract][Full Text] [Related]
24. siRNA delivery systems for cancer treatment. Oh YK; Park TG Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869 [TBL] [Abstract][Full Text] [Related]
25. RNAi nanomedicines: challenges and opportunities within the immune system. Weinstein S; Peer D Nanotechnology; 2010 Jun; 21(23):232001. PubMed ID: 20463388 [TBL] [Abstract][Full Text] [Related]
27. RNA interference: a tool for querying nervous system function and an emerging therapy. Davidson BL; Boudreau RL Neuron; 2007 Mar; 53(6):781-8. PubMed ID: 17359914 [TBL] [Abstract][Full Text] [Related]
28. Short interfering RNA (siRNA): tool or therapeutic? Cejka D; Losert D; Wacheck V Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204 [TBL] [Abstract][Full Text] [Related]
29. [Therapeutic RNA interference for neurodegenerative diseases]. González-Alegre P Rev Neurol; 2008 Dec 16-31; 47(12):641-7. PubMed ID: 19085881 [TBL] [Abstract][Full Text] [Related]
30. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. Aigner A J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817 [TBL] [Abstract][Full Text] [Related]
32. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Akhtar S; Benter I Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774 [TBL] [Abstract][Full Text] [Related]
33. Combined lentiviral and RNAi technologies for the delivery and permanent silencing of the hsp25 gene. Kaur P; Nagaraja GM; Asea A Methods Mol Biol; 2011; 787():121-36. PubMed ID: 21898232 [TBL] [Abstract][Full Text] [Related]
34. [RNA interference (RNAi) and its therapeutic potential in cancer]. Vázquez-Vega S; Contreras-Paredes A; Lizano-Soberón M; Amador-Molina A; García-Carrancá A; Sánchez-Suárez LP; Benítez-Bribiesca L Rev Invest Clin; 2010; 62(1):81-90. PubMed ID: 20415062 [TBL] [Abstract][Full Text] [Related]
35. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. Saydam O; Saydam N; Glauser DL; Pruschy M; Dinh-Van V; Hilbe M; Jacobs AH; Ackermann M; Fraefel C Gene Ther; 2007 Aug; 14(15):1143-51. PubMed ID: 17495946 [TBL] [Abstract][Full Text] [Related]